SII will buy 20 percent stake in Integrimedical
New Delhi, Vaccine maker Serum Institute of India (SII) on Friday said it is acquiring 20 per cent stake in Integrimedical to advance needle-free injection system technology. IntegriMedical has developed a US-patented needle-free injection system (N-FIS) that uses mechanical power to effectively administer biologics and drugs through high-speed injection, Serum Institute of India (SII) said in a statement. Velocity uses the jet stream. However, the company did not disclose financial details of the transaction. The innovative drug delivery solution aims to minimize pain during administration, providing a stress-free experience to needle-phobic patients. “IntegriMedical's N-FIS represents a significant advancement in drug delivery and we envision a needle-free solution for delivering vaccines. We believe this could potentially revolutionize the way we administer vaccines, making the process more comfortable for patients and health care professionals,” said SII CE Adar Poonaw...